Profil
Dr. Chris Wahl is a Chief Scientific Officer at Halozyme Therapeutics, Inc. Dr. Wahl was previously employed as a Vice President-Strategy & Business Development by Biora Therapeutics, Inc., a Chief Operating Officer by Interface Therapeutics, Inc., and a Chief Operating Officer by Micropharma Ltd. He received his undergraduate degree from Lee University, an MBA from McGill University and a doctorate degree from McGill University.
Aktiva positioner av Chris Wahl
| Företag | Position | Start |
|---|---|---|
| HALOZYME THERAPEUTICS, INC. | Teknisk/Vetenskaplig/F&U Direktör | - |
Tidigare kända positioner av Chris Wahl
| Företag | Position | Slut |
|---|---|---|
| BIORA THERAPEUTICS, INC. | Företagsledare/Principal | - |
Interface Therapeutics, Inc. | Grundare | - |
Micropharma Ltd.
Micropharma Ltd. Pharmaceuticals: MajorHealth Technology Formulates, manufactures & sells functional food, neutraceuticals and pharmaceutical products | Verksamhetschef | - |
Chris Wahls utbildningar
Erfarenheter
Innehade positioner
Aktiva
Inaktiva
Börsnoterade företag
Privata företag
Relationer
Första gradens relationer
Företag kopplade till första graden
Man
Kvinna
Styrelseledamöter
Chefer
Kopplade företag
| Privata företag | 6 |
|---|---|
Halozyme Therapeutics, Inc.
Halozyme Therapeutics, Inc. BiotechnologyHealth Technology Engages in the development and commercialization of recombinant human enzymes for the infertility, ophthalmology & oncology markets | Health Technology |
Micropharma Ltd.
Micropharma Ltd. Pharmaceuticals: MajorHealth Technology Formulates, manufactures & sells functional food, neutraceuticals and pharmaceutical products | Health Technology |
McGill University
McGill University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Lee University
Lee University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Biora Therapeutics, Inc.
Biora Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biotechnology company focused on developing targeted therapies for cancer and autoimmune diseases | Health Technology |
Interface Therapeutics, Inc. |
















